With the dawn of novel technology era, companies operating in the healthcare/science/pharmaceutical/therapeutic industries are now surmounting the never touched peaks. Also the growth of these industries is overhauled by the unrelenting increase in health related issues emanating from the altering lifestyle and rapidly evolving surrounding environment. Amongst the respective industries of biological sciences, a booming industry is of IV (Intravenous) iron. Iron is one of the most crucial elements required by the human body. It is a component of hemoglobin, the substance present in RBCs that transports oxygen throughout the body via blood. This oxygen is used by the cells for generating energy required to perform the necessary body functions. So, if the body’s iron levels fall below the accepted line, it can lead to severe health problems. Usually oral iron supplements are recommended for restoring and maintaining iron levels in the body, but oral treatment has certain limitations. For the cases where oral supplements are incapable of fulfilling the purpose, IV iron therapy is used as part of which iron is directly injected with a needle into a vein. This report offers comprehensive analysis of the global iron products market along with the key segments viz. IV Iron and Oral Iron. Herein, the IV iron market is discussed in details. Also, the IV iron replacement therapy market of the US is covered. Furthermore, market dynamics including the key trends and developments, underlying industry growth drivers and the challenges faced by the respective market are analyzed in-depth. On the contention front, the market for IV iron is highly competitive with a handful of players dominating the whole market. The competitive landscape along with the profiles of leading industry players is also included in this report.

1. Global Intravenous (IV) Iron Drugs Market
------------------------------------------------------------
2013
View Report Details

2. Executive Summary
With the dawn of novel technology era, companies operating in the healthcare/science/pharmaceutical/therapeutic industries are
now surmounting the never touched peaks. Also the growth of these industries is overhauled by the unrelenting increase in health
related issues emanating from the altering lifestyle and rapidly evolving surrounding environment. Amongst the respective
industries of biological sciences, a booming industry is of IV (Intravenous) iron.
Iron is one of the most crucial elements required by the human body. It is a component of hemoglobin, the substance present in
RBCs that transports oxygen throughout the body via blood. This oxygen is used by the cells for generating energy required to
perform the necessary body functions. So, if the body’s iron levels fall below the accepted line, it can lead to severe health
problems. Usually oral iron supplements are recommended for restoring and maintaining iron levels in the body, but oral
treatment has certain limitations. For the cases where oral supplements are incapable of fulfilling the purpose, IV iron therapy is
used as part of which iron is directly injected with a needle into a vein.
This report offers comprehensive analysis of the global iron products market along with the key segments viz. IV Iron and Oral
Iron. Herein, the IV iron market is discussed in details. Also, the IV iron replacement therapy market of the US is covered.
Furthermore, market dynamics including the key trends and developments, underlying industry growth drivers and the challenges
faced by the respective market are analyzed in-depth. On the contention front, the market for IV iron is highly competitive with a
handful of players dominating the whole market. The competitive landscape along with the profiles of leading industry players is
also included in this report.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future
growth of the industry. We employed various significant variables that have an impact on this industry and created regression
models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship
between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output,
including charts, tables and tests.
View Report Details

3. The balance of iron in the body primarily is a combined result of three dynamics- intake, losses and
metabolic demand…
•Iron is among the most crucial elements required for red blood cell
production, and iron homeostasis i.e. the body’s internal regulation of
iron. It is one of the key functions which gets disrupted in dialysis
patients. Iron deficiency, either absolute or functional, is a primary
cause of anemia in hemodialysis patients.
•The worldwide market for iron related products was valued at
US$.......... billion in 2012, experiencing a decline of ………% against
US$............. billion in 2011. Over the time span of 4 years from 2008 to
2012, the global market for iron products recorded a CAGR of ……….%
and increased from US$..........billion in 2008 to US$................billion in
2012.
•As of 2012, the overall iron products market was dominated by the oral
iron medication with share worth …………% while IV iron constituted
the remaining …………….% of the respective market.
Industry Trends and Developments
-New Product Development- Soluble Ferric Pyrophosphate (SFP)
-Bundled Payment System
Challenges
-Stringent Regulation
-Concerns Regarding Adverse Effects
Oral Intavenous
Global Iron Products Market (2008-2012)
Global Iron Products Market Share (2012)
2008 2009 2010 2011 2012
US$Billion

4. The cases, where oral supplements fail to meet the requirement, IV iron therapy is used, as part of which
iron is directly injected with a needle into a vein….
•The IV iron market was valued at US$...........million in 2011, and
registered a decline of …….% to US$...... million in 2012. During 2008-
2012, the worldwide market for IV iron increased at the compound
annual growth rate of …….%.
•In the US, at present there are three primary IV iron agents viz.
Venofer (iron sucrose), Ferrlecit (sodium ferric gluconate), and
Feraheme (ferumoxytol) which are used in dialysis facilities for treating
iron deficiency. As of 2011, the US IV iron market reached
US$...........million recording a decline of ……..% as compared to the
value of US$.........million in 2010.
•On an estimated basis, the size of the total 2012 US non-dialysis IV
iron replacement therapy market was approximately …………. grams,
which depicted an increase of nearly ……..% over 2011 when the size
was ………. grams.
US Non-Dialysis IV Iron Market (2011 & 2012)The US IV Iron Market Size (2008-2011)
)
Global IV Iron Market (2008-2012)
2008 2009 2010 2011
US$Million
2008 2009 2010 2011 2012
US$Million
2011
2012
Grams

5. Branded IV iron products include Venofer, Ferrlecit, Monofer, Ferinject (ferric carboxymaltose injection)
and certain other iron dextran and iron sucrose products….
As per the estimates, the total size of the US non-dialysis IV iron replacement therapy market observed an increase
of approximately ………% over 2011. The leading product in the year 2012, in the US non-dialysis IV iron market was
Venofer with ……..% market share.
Oral iron is currently the first-line iron replacement alternative preferred by majority of the physicians in both the US
and abroad. IV irons are best suited for those patients whose ferritin, fundamentally storage iron, levels have been
profoundly depleted.
There are five key IV irons that are on the market or in development: Watson’s INFeD, Luitpold Pharmaceuticals’
Venofer, Sanofi’s Ferrlecit, AMAG Pharmaceuticals’ Feraheme, and Luitpold’s Injectafer.
The global IV iron market, which is estimated to reach US$........ million in 2015 from US$.........million in 2012. During
the 3 year period from 2012 to 2015, the global market for IV iron is expected to grow at a CAGR of ……….%.
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa
2010 2011 2012 2013E 2014E 2015E
US$Billion
Global IV Iron Market Forecast (2010-2015E)
Venofer Luitpold Pharm Inc. Brand
Venofer Fresenius Kabi Branded Generic
Nulecit Watson Pharma Branded Generic
Infed Watson Pharma Branded Generic
Ferrlecit Sanofi Aventis Branded Generic
Feraheme AMAG Pharm Branded Generic
Others
IV Iron Market Share in the US (January 2012)

6. Table of Contents
1. Iron in Human Body: An Overview
1.1 IV Iron Application Areas
1.1.1 IV Iron Application in Nephrology
1.2 Iron Deficiency- Anemia
1.3 IV Iron Therapy for Anemia Treatment
2. Iron Medication Market Structure
2.1 Global Iron Products Market
-Market Value
-Market Segments
2.1.1 Global IV Iron Market
-Market Value
2.2 The US IV Iron Market
-Market Value
-Non-Dialysis IV Iron Market
3. Market Dynamics
3.1 Industry Trends and Developments
3.1.1 New Product Development- Soluble Ferric
Pyrophosphate (SFP)
3.1.2 Bundled Payment System
3.2 Growth Drivers
3.2.1 Increasing Use of IV Iron in Gynecology
3.2.2 IV Iron Improves Quality of Treatment outside
Dialysis
3.2.3 Increasing Dialysis Patient Population
3.2.4 Growing Number of Diabetic Patients Worldwide
3.2.5 Increasing Cases of Hypertension
List of Charts & Tables
List of Charts
Global Iron Products Market (2008-2012)
Global Iron Products Market Share (2012)
Global IV Iron Market (2006-2010)
The US IV Iron Market Size (2008-2011)
US Non-Dialysis IV Iron Market (2011 & 2012)
IV Iron – Avoidance of ESA Initiation in Pre Dialysis Patients
IV Iron – Response Rate to ESA with/without IV Iron (2004-2011)
Dialysis Patient Population Worldwide (2005-2015E)
Dialysis Patient Population Share by Region (2011)
Global Diabetes Population (2006-2011)
Causes of ESRD in the US (2011)
Worldwide Patients with End Stage Renal Disease (2005-2011)
Hypertension Prevalence in the US (2010-2015E)
Hypertension Prevalence in the Developed Europe (2010-2015E)
Global Healthcare Spending (2005-2015E)
Global Spending on Medicines (2006-2016E)
Global Spending on Medicine Share by Region (2006-2016E)
The US Spending on Medicine (2007-2016E)
Japan’s Spending on Medicine (2007-2016E)
Global Ageing Population (2005-2013F)
Global GDP (2001-2011)
World GDP per Capita (2005-2011)
Global Insurance Density (2004-2011)
Long and Short Term Concerns about IV Iron
IV Iron Market Share in the US (January 2012)
Galenica’s Revenue Share by Business Segments (2012)
Galenica’s Net Sales and Net profit (2009-2012)
Actavis’ Revenue Share by Business Segment (2012)
Actavis’ Revenues and Net Income (2009-2012)
AMAG Pharmaceuticals’ Revenues (2009-2012)
Global IV Iron Market Forecast (2010-2015E)

7. 3.2.6 Rising Healthcare Expenditure
3.2.7 Higher Spending on Medicines
3.2.8 Growing Ageing Population (+60 Years)
3.2.9 Ameliorating Economic Conditions
3.2.10 Increasing Insurance Density
3.3 Challenges
3.3.1 Stringent Regulation
3.3.2 Concerns Regarding Adverse Effects
4. Competitive Landscape
4.1 US Market
4.2 Product Contention
5. Company Profiles
5.1 Galenica Pharmaceuticals
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Strong Foothold in Healthcare Market
-Focus on New Product Development
5.2 Actavis Inc.
5.2.1 Business Description
5.2.2 Financial Overview
5.2.3 Business Strategies
-Strategic Acquisitions
-Intense R&D Activities
5.3 AMAG Pharmaceuticals
5.3.1 Business Oveview
5.3.2 Financial Overview
5.3.3 Business Strategies
-Focus on Research & Development
-Expanding the Existing Labels
List of Tables
Risk Factors for CKD
SFP Clinical Trials
IV Iron Products – Safety Profile
The US Non-Dialysis IV Iron Market (2011 & 2012)
IV Iron Administration Comparison
Dependent & Independent Variables (2006-2010)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output

8. 6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

9. Koncept Analytics
CS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T. +91-120-4130959
C: +91-9811715635
vikas@konceptanalytics.com
Contact Us:
www.konceptanalytics.com
Vikas Gupta
BD Manager
These are abridged and sanitized sample pages from the comprehensive report on the “Global Intravenous (IV) Iron Drugs
Market ”. To know more about this report or for any customized research requirement, please contact the following:
View Report Details